Our Next Show: How Sugar Molecules Act as a Multiple Myeloma Smoke Screen with Michael O’Dwyer, MD, NUI Galway, Friday, August 25 @ 11 am Central
Friday, August 25, 2017 @ 9 am Pacific, 10 am Mountain, 11 am Central, Noon…
Author Jenny A
Jenny A
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.
Eclipse Camp 2017 in Rexburg, Idaho, August 19-21, 2017
To date, the Myeloma Crowd Research Initiative has raised $477,000 towards our $500,000 goal. The…
Stem Cell Transplant’s Impact on Relapsed Myeloma
When proteasome inhibitors (like bortezomib) and immunomodulators (like lenalidomide) were introduced in the early 2000s…
Clinical Trial: Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Daratumumab is a newer immunotherapy approved by the FDA for relapsed myeloma. Because it has…
Clinical Trial: Myeloma Cell-Targeted Ionizing Radiation Using I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
The radiosensitivity of multiple myeloma is well documented. A new drug in clinical trials called…
Full Show: The Latest in Myeloma Therapy Advances with Sagar Lonial, MD, Winship Cancer Institue, Emory University
Sagar Lonial, MD Winship Cancer Institute Interview Date: July 19, 2017 Summary Recent meetings held…
Blood Cancer Phase I NK Cell Clinical Trial Shows Durable Complete Responses
An immunotherapy called natural killer (NK) cells can be used with your own NK cells…
Clinical Trial: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
Smoldering myeloma (SMM) is considered a precursor of multiple myeloma for a percentage of patients.…
Myeloma 101: What is a “Line” of Therapy in Multiple Myeloma?
Many myeloma clinical trials include approval criteria based on the number of “lines” of therapy…
Considerations on Cost and Convenience of Multiple Myeloma Therapy
If you have multiple myeloma, you’re certainly familiar with spending time in the clinic. Some…
Our Next Show: ASCO and EHA Myeloma Meeting Updates with Sagar Lonial, MD, Winship Cancer Institute, Wednesday, July 19 @ 2 pm Eastern
Wednesday, July 19, 2017 @ 11 am Pacific, Noon Mountain, 1 pm Central, 2 pm…
FDA Panel Recommends Approval for Novartis CAR T Cell Treatment in Leukemia
The Food and Drug Administration panel opened the door to widespread use of CAR T…
Hope vs. Hype in New Cancer Therapies
Over the last few years, cancer patients have become ever hopeful that a cure is…
Clinical Trial: For Patients Resistant to Lenalidomide, the Antibody Elotuzumab With the Newer Pomalidomide and Dex for Relapsed/Refractory Myeloma
Since its approval in the fall of 2015, the monoclonal antibody elotuzumab (Empliciti) has been…
Second Study Shows Kyprolis® Improves Overall Survival for Relapsed/Refractory Myeloma
Final results from the Phase III ASPIRE study were published by Amgen showing that carfilzomib…
Patient Power: Progress in Immunotherapies and Precision Medicine
Dr. Hearn Jay Cho of Mount Sinai Hospital joined Andrew Schorr of Patient Power at…
MCRI Update: CAR T Cell Research, University of Würzburg
The Myeloma Crowd funded two key immunotherapy projects as part of the Myeloma Crowd Research…
EHA 2017: Elotuzumab Shows Long-Term Impact in 4-Year Study Follow-Up
Bristol-Myers Squibb presented four year updated data from their ELOQUENT-2 Trial, a trial enrolling 646…
FDA Places Keytruda Multiple Myeloma Studies on Hold
Merck & Co announced today that the FDA had placed a clinical hold on three…
Clinical Trial: Antibody Phase I Study Targeting CD-352 for Relapsed/Refractory Myeloma Patients
A Phase I clinical trial testing an antibody that targets CD-352 is open for multiple…
September 30, 2017, Myeloma Crowd Round Tables: New York, NY
Myeloma Crowd Round Tables are day-long meetings that provide patients and caregivers updated information so…
Myeloma 101: When Does Smoldering Myeloma Become Active Myeloma?
Smoldering myeloma is a precursor stage of multiple myeloma. Historically, smoldering myeloma patients have not…
EHA 2017: Newly Diagnosed Myeloma
Today many newly diagnosed myeloma patients will receive induction therapy and then go to stem…
EHA 2017: The Nature of Long Remissions
“I still haven’t found what I’m looking for.” U2 What makes one patient’s remission longer…
EHA 2017: The Art of Treating Multiple Myeloma
“The arrival of new effective drugs in such a short period of time is making…
EHA 2017: Myeloma Treatment for the Elderly or Transplant Ineligible
Myeloma therapy is getting better for elderly patients according to Graham Jackson, MD and Professor…
EHA 2017: Managing Myeloma Drug Side Effects
Today is the first day of the European Hematology Conference in Madrid, Spain. We will…
Full Show: New Bi-Specific Antibody Hitting Two Targets in Myeloma, Dirk Hose, MD and Anja Seckinger, MD, University of Heidelberg
Dirk Hose, MD Anja Seckinger, MD Interview Date: May 24, 2017 Summary Many myeloma patients…
ASCO 2017: Three Studies for Newly Diagnosed Multiple Myeloma
Three studies were reported on at the recent ASCO 2017 conference that were specific to…
A Cancer Caregiver’s Open Letter to Family and Friends: Please Understand, Life After Cancer is Different
Every patient agrees that once you’ve been diagnosed with cancer, there is no going back…
Muscles for Myeloma Columbus Run Raises $30,000 for Multiple Myeloma Research
The Myeloma Crowd hosted it’s first Muscles for Myeloma Columbus 5K and 1 Mile Race,…
ASCO 2017: CAR T Cell Therapy Shows Incredible Results in Myeloma
At the recent ASCO 2017 conference, CAR T cell therapy demonstrated unprecedented results in several…
ASCO 2017: New Myeloma Bone Strengthener Shows Equal Benefit Compared to Zoledronic Acid
At the recent American Society of Clinical Oncology (ASCO) conference, Amgen presented data from a…
Artificial Virus May Become Foundation for Innovative Cancer Treatment
Swiss scientists from the University of Geneva (UNIGE), Switzerland, and the University of Basel have…
Clinical Trial: More Options for Patients Refractory to Lenalidomide
Over the course of their care, patients may become refractory to one of the mainstay…
Keytruda, Pomalidomide and Dex Combination May Provide Impact for Relapsed/Refractory Myeloma Patients
The triple combination of pembrolizumab (Keytruda), pomalidomide and low dose dexamethasone was recently studied at the…
Fighting Cancer Is Hard. 15 Tips for Living With Chronic Illness
BY KIM GILES Find the original article on KSL. CC Scott said, “The human spirit…
Clinical Trial: Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed/Refractory Multiple Myeloma
A clinical trial is open so study Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed…
Living Long-Term With Myeloma Part 2: Renal Function
This is the second in a series based on “Guidelines for screening and management of…
September 23, 2017, Myeloma Crowd Round Tables: Detroit, Michigan
Myeloma Crowd Round Tables are day-long meetings that provide patients and caregivers updated information so…
Myeloma Crowd Research Initiative (MCRI) Funds Two Immunotherapy Projects
The Myeloma Crowd Initiative selected two proposals it has selected for the MCRI crowdsourcing and…
Continuing the Fight for a Myeloma Cure: Dr. Tricot and Dr. Zhan’s Research to Improve Outcomes for High-Risk Myeloma Patients
Guido Tricot, MD, PhD has devotedly attended to thousands of multiple myeloma patients for over…
Minimal Residual Disease Negativity Becomes the New End Point in Myeloma Therapy
In a recent ASCO article by French myeloma specialists Jean-Luc Harousseau and Herve Avet-Loisea and…
Clinical Trial: FDA Approved Drugs in Other Cancers (Dabrafenib/Trametinib) Now Used In Early Myeloma Clinical Trial for Relapsed/Refractory Patients
The drugs Trametinib or Dabrafenib have been FDA approved in other cancers. Some cancers, including myeloma,…
Our Next Show: Targeting BCMA and T Cells in New Bi-Specific Myeloma Antibody with Anja Seckinger, MD and Dirk Hose, MD, University of Heidelberg, Wednesday, May 24 @ 10 am Central
Wednesday, May 24, 2017 @ 8 am Pacific, 9 am Mountain, 10 am Central, 11…
New Drug that Redirects Immune Cells Towards Myeloma Tumor Cells Cleared by FDA for Clinical Trial
The FDA has approved a new drug application by Glenmark Pharmaceuticals to begin a phase…
New Drug GMI-1271 May Help Velcade Work Again in Relapsed Myeloma
Velcade is an effective treatment for multiple myeloma, but some patients’ myeloma can become resistant…
Comparing Myeloma Minimal Residual Disease Tests: EuroFlow vs. New MSKCC Test
Evaluating myeloma patients after treatment with more sensitive testing to see how much disease is…
Clinical Trial: MGUS and Smoldering Myeloma Observational Study on Genomic Predictors of Progression
Why do some patients with monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM)…
Muscles for Myeloma: Your Healthier and Happier Self in 2017
Thanks for joining Muscles for Myeloma in 2017! During this year’s campaign, almost 20,000 of…